Status:
UNKNOWN
1,5 Anhydroglucitol and 1,5 Anhydroglucitol / Glycated Hemoglobin Ratio as a Potential Biomarker for Islet β-cell Function and Insulin Resistance Among Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
Cairo University
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
20-70 years
Brief Summary
Hyperglycemia is a major risk factor for the micro- and macro-vascular complications of diabetes . Lowering blood glucose levels has been shown to reduce the incidence of diabetes complications. Ther...
Eligibility Criteria
Inclusion
- Men and women aged 20 to 70 years old with controlled and uncontrolled type 2 DM.
Exclusion
- : type 1 DM,
- thyroid dysfunction,
- chronic kidney disease,
- chronic liver disease,
- cancer patients,
- cystic fibrosis,
- acute and chronic infection and
- pregnancy
Key Trial Info
Start Date :
May 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04869605
Start Date
May 6 2021
End Date
October 1 2022
Last Update
March 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Manial, Egypt, 11521